• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Medtronic launches 7-day infusion set for insulin pumps in U.S.

November 15, 2022 By Sean Whooley

Medtronic Extended Wear Infusion Set Insulin Delivery Diabetes
[Image from Medtronic]
Medtronic (NYSE:MDT) announced today that it launched its Medtronic Extended Infusion set for seven-day wear with insulin delivery.

The Medtronic Extended Infusion Set represents the first and only infusion set labeled for wearing of up to seven days. The infusion set for delivering insulin from a pump to the body typically requires changing every two to three days. It is available exclusively for customers using MiniMed 600 and 700 series pumps. Medtronic developed it in partnership with Convatec Infusion Care.

Medtronic designed its infusion set with advanced materials for reducing insulin preservative loss and maintaining insulin flow. This helps provide stability, doubling the wear time of a typical infusion set. It leverages proprietary technology, including a new tubing connector for improving insulin’s physical and chemical stability. The connector also enhances the reliability of infusion site performance and reduces the risk of infusion set occlusion.

The system also features an adhesive patch with a layer that helps extend wear time and provide comfort and durability. Medtronic said its Extended reservoir represents the only infusion set reservoir tested and cleared for this duration, too.

“When patients first begin using a pump, doctors and other healthcare providers reinforce the need to change their infusion set every two to three days to limit the risk of infection and other safety concerns. For many people, this means scheduling life around infusion set changes, which may not be at the most convenient times ― turning around as you are headed out the door when you suddenly remember to change your infusion set or adding a few minutes to a tired child’s bedtime routine with an infusion set change,” said Dr. Robert Vigersky, CMO, Medtronic Diabetes. “With the Medtronic Extended infusion set, these life interruptions are reduced with an innovation that doubles the wear.”

About the benefits of the infusion set

Studies demonstrated a decrease in the number of changes for the infusion set by 50%. Users also observed lower infusion set failures associated with high glucose levels. Participants stated that the new infusion set offered more comfortability compared to their previous sets. They presented happiness with the longer wear time as it helped reduce the overall burden of insulin pump therapy.

Medtronic Extended Infusion Set Insulin Delivery Diabetes on person
[Image from Medtronic]
Additionally, Medtronic said its Extended set could provide insulin cost savings of up to 25%. This is due to a reduced number of set and reservoir changes that result in unrecoverable insulin. It also attributed this to up to 50% in plastic waste reduction.

“Our goal is to make life easier for individuals living with diabetes and the Medtronic Extended infusion set helps us deliver on this with prolonged and more comfortable wear – something customers have been requesting for many years,” said Que Dallara, EVP & president, Medtronic Diabetes. “We couldn’t be more pleased to launch this innovation during Diabetes Awareness Month when we take the time to reflect on what more we can do to alleviate the burden for those living with this chronic condition.

“We’re pleased to deliver a groundbreaking innovation that will make a real difference in the overall pump experience given the overwhelming and well-documented benefits of this therapeutic option.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured Tagged With: Medtronic

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS